Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Am J Hum Genet. 2020 Sep 3;107(3):555-563. doi: 10.1016/j.ajhg.2020.07.003. Epub 2020 Aug 5.
Helsmoortel-Van der Aa syndrome (HVDAS) is a neurodevelopmental condition associated with intellectual disability/developmental delay, autism spectrum disorder, and multiple medical comorbidities. HVDAS is caused by mutations in activity-dependent neuroprotective protein (ADNP). A recent study identified genome-wide DNA methylation changes in 22 individuals with HVDAS, adding to the group of neurodevelopmental disorders with an epigenetic signature. This methylation signature segregated those with HVDAS into two groups based on the location of the mutations. Here, we conducted an independent study on 24 individuals with HVDAS and replicated the existence of the two mutation-dependent episignatures. To probe whether the two distinct episignatures correlate with clinical outcomes, we used deep behavioral and neurobiological data from two prospective cohorts of individuals with a genetic diagnosis of HVDAS. We found limited phenotypic differences between the two HVDAS-affected groups and no evidence that individuals with more widespread methylation changes are more severely affected. Moreover, in spite of the methylation changes, we observed no profound alterations in the blood transcriptome of individuals with HVDAS. Our data warrant caution in harnessing methylation signatures in HVDAS as a tool for clinical stratification, at least with regard to behavioral phenotypes.
赫尔姆斯-沃特德尔-范德阿综合征(Helsmoortel-Van der Aa syndrome,HVDAS)是一种与智力障碍/发育迟缓、自闭症谱系障碍和多种医学合并症相关的神经发育状况。HVDAS 是由活性依赖性神经保护蛋白(ADNP)突变引起的。最近的一项研究在 22 名 HVDAS 患者中发现了全基因组 DNA 甲基化变化,这增加了具有表观遗传特征的神经发育障碍群体。该甲基化特征根据突变的位置将具有 HVDAS 的个体分为两组。在这里,我们对 24 名 HVDAS 患者进行了一项独立研究,并复制了存在的两种突变依赖的表观遗传特征。为了探究这两种不同的表观遗传特征是否与临床结果相关,我们使用了来自两个具有 HVDAS 遗传诊断的前瞻性队列的深度行为和神经生物学数据。我们发现,两组 HVDAS 受影响的个体之间存在有限的表型差异,没有证据表明广泛的甲基化变化个体受到更严重的影响。此外,尽管存在甲基化变化,我们在 HVDAS 个体的血液转录组中没有观察到明显的改变。我们的数据在将 HVDAS 中的甲基化特征作为临床分层的工具方面需要谨慎,至少在行为表型方面是如此。